Shorter immunotherapy duration for advanced melanoma shows comparable disease control in UK DANTE trial Read more
TAGRISSO reduces disease progression or death by 84 % in Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial Read more